[ Cybrexa Therapeutics raises $6M in Series B ]
Cybrexa Therapeutics has raised $6 million in Series B funding.
Founded in 2017, Cybrexa Therapeutics is a biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors (TSDs) that directly target the tumor microenvironment.
The company will use the fresh money to complete the build-out of its facilities and continue the development its tumor-localizing DNA repair inhibitors, which they refer to as Tumor Specific Drugs (TSDs).
|City||New Haven, Connecticut|
|Founder / CEO||Per Hellsund|